Lantern Pharma is proud to be featured by a multitude of media outlets. Our goal is to crush cancer, and by spreading word of our innovative technology we hope to open the door to more collaborations and partnerships than ever, to empower us to develop the right treatments for the right patients.
WedJul 28th, 2021
How AI Is Expediting Medicine Development
By Panna Sharma, RealClearMarkets
MonJul 26th, 2021
Allarity Therapeutics, Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
By Charles Gross, Benzinga
TueJul 20th, 2021
Preclinical Data on New Pancreatic Cancer Drug Shines with over 90% Efficacy
By Vanessa Doctor, RN, BioSpace
TueJul 20th, 2021
Midday Hot Stocks: SPCE falls as Bezos flies; HAL, UBS rise on earnings; LTRN gets strong pre-clinical data
By Brian Stewart, Seeking Alpha
FriJul 9th, 2021
TueApr 13th, 2021
New Lantern Manuscript: The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations
By: Aditya Kulkarni, Joseph Ryan McDermott, Umesh Kathad, Rama Modali, [...]